New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 11, 2014
06:39 EDTMNK, QCORQuestcor reports Acthar adverse effects data, NY Times says
The number of patients who reported an adverse effect last year while taking Questcor's (QCOR) Acthar drug amounted to almost 5% of prescriptions dispensed, the company stated in a regulatory filing released yesterday, according to The New York Times. The filing marked the first time that the company has disclosed any difficulties experienced by Acthar patients, the newspaper added. Questcor has agreed to be bought by Mallinckrodt (MNK). Reference Link
News For QCOR;MNK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 31, 2015
07:25 EDTMNKTeva upgraded at Oppenheimer
Subscribe for More Information
March 27, 2015
07:57 EDTMNKMallinckrodt announces positive outcomes with H.P. Acthar gel in proteinuria
Subscribe for More Information
March 26, 2015
07:30 EDTMNKDeutsche Bank to hold a conference
Pharma One-on-One Day is being held in Denver, Colorado on March 26.
March 23, 2015
13:23 EDTMNKLeerink pharma/generics analyst has analyst/industry conference call
Specialty Pharmaceuticals/Generics Analyst Gerberry, discusses the strengths and weaknesses of INOmax's current patent portfolio, the likelihood Praxair's recently filed inter-partes review challenge succeeds on an Analyst/Industry conference call to be held on March 26 at 2 pm.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use